A. W. Armstrong, “Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial”, J of Skin, vol. 6, no. 6, p. s62, Nov. 2022.